Bone marrow and splenocyte analysis of transplanted mice at the time of death
| . | No. mice, phenotype . | Bone marrow . | Splenocytes . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| % GFP+ . | % CD19+ . | % GR1+ . | % B220+ . | % MPO+ . | % CD117+ . | % GFP+ . | % CD19+ . | % GR1+ . | % CD117+ . | ||
| Control | 7 None | 1.4 (0.7-6.7) | 19.9 (7.7-27.2) | 66.8 (41.6-82.1) | 24.9 (9.9-45.3) | 0.5 (0.2-2.9) | 12.8 (4.0-22.6) | 2.3 (0.8-11.4) | 42.6 (23.6-53.0) | 18.7 (8.8-24.2) | 4.4 (1.1-9.1) |
| SOCS1 | 10 None | 0.3 (0.0-1.4) | 33.4 (12.1-43.1) | 58.5 (40.6-85.3) | 34.4 (19.9-49.2) | 7.2 (0.3-18.5) | 0.3 (0.0-1.4) | 56.2 (24.1-61.4) | 11.4 (1.4-25.9) | 3.2 (0.2-4.3) | |
| FLT3-ITD | 12 MPD | 91.3 (21.8-97,6) | 94.7* (8.2-98.6) | 0.0 (0.0-66.4) | 73.9 (11.2-84.4) | 12.4 (6.4-20.0) | 0.3 (0.0-6.2) | 82.6 (45.4-95) | 93.9* (1.9-97.6) | 0.0 (0.0-66.7) | 0.2 (0.0-7.4) |
| 6 ALL | 90.6 (36.6-94.0) | 96.8 (69.7-97.5) | 0.0 (0.0-1.8) | 75.8 (38.9-83.5) | 7.2 (6.7-10.0) | 0.2 (0.1-1.5) | 76.2 (26.1-84.9) | 94.2 (13.3-96.2) | 0.1 (0.0-6.9) | 0.1 (0.1-7.5) | |
| SOCS1-T2A-FLT3-ITD | 11 MPD | 78.9 (22.6-95.2) | 92.8* (5.1-99.2) | 0.0 (0.0-56.2) | 87.0 (3.1-93.4) | 10.2 (8.7-78.0) | 0.2 (0.0-2.5) | 63.9 (47.8-92.4) | 94.8* (2.6-98.8) | 0.2 (0.0-38.9) | 0.6 (0.1-2.6) |
| 11 ALL | 89.2 (39.8-96.9) | 94.7 (74.6-99.1) | 0.1 (0.0-19.3) | 80.7 (12.9-93.8) | 4.2 (2.9-6.9) | 0.2 (0.0-3.8) | 89.3 (24.2-94.3) | 94.8 (87.4-98.8) | 0.2 (0.0-7.5) | 0.5 (2.5-6.0) | |
| . | No. mice, phenotype . | Bone marrow . | Splenocytes . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| % GFP+ . | % CD19+ . | % GR1+ . | % B220+ . | % MPO+ . | % CD117+ . | % GFP+ . | % CD19+ . | % GR1+ . | % CD117+ . | ||
| Control | 7 None | 1.4 (0.7-6.7) | 19.9 (7.7-27.2) | 66.8 (41.6-82.1) | 24.9 (9.9-45.3) | 0.5 (0.2-2.9) | 12.8 (4.0-22.6) | 2.3 (0.8-11.4) | 42.6 (23.6-53.0) | 18.7 (8.8-24.2) | 4.4 (1.1-9.1) |
| SOCS1 | 10 None | 0.3 (0.0-1.4) | 33.4 (12.1-43.1) | 58.5 (40.6-85.3) | 34.4 (19.9-49.2) | 7.2 (0.3-18.5) | 0.3 (0.0-1.4) | 56.2 (24.1-61.4) | 11.4 (1.4-25.9) | 3.2 (0.2-4.3) | |
| FLT3-ITD | 12 MPD | 91.3 (21.8-97,6) | 94.7* (8.2-98.6) | 0.0 (0.0-66.4) | 73.9 (11.2-84.4) | 12.4 (6.4-20.0) | 0.3 (0.0-6.2) | 82.6 (45.4-95) | 93.9* (1.9-97.6) | 0.0 (0.0-66.7) | 0.2 (0.0-7.4) |
| 6 ALL | 90.6 (36.6-94.0) | 96.8 (69.7-97.5) | 0.0 (0.0-1.8) | 75.8 (38.9-83.5) | 7.2 (6.7-10.0) | 0.2 (0.1-1.5) | 76.2 (26.1-84.9) | 94.2 (13.3-96.2) | 0.1 (0.0-6.9) | 0.1 (0.1-7.5) | |
| SOCS1-T2A-FLT3-ITD | 11 MPD | 78.9 (22.6-95.2) | 92.8* (5.1-99.2) | 0.0 (0.0-56.2) | 87.0 (3.1-93.4) | 10.2 (8.7-78.0) | 0.2 (0.0-2.5) | 63.9 (47.8-92.4) | 94.8* (2.6-98.8) | 0.2 (0.0-38.9) | 0.6 (0.1-2.6) |
| 11 ALL | 89.2 (39.8-96.9) | 94.7 (74.6-99.1) | 0.1 (0.0-19.3) | 80.7 (12.9-93.8) | 4.2 (2.9-6.9) | 0.2 (0.0-3.8) | 89.3 (24.2-94.3) | 94.8 (87.4-98.8) | 0.2 (0.0-7.5) | 0.5 (2.5-6.0) | |
Mice transplanted with bone marrow expressing FLT3-ITD or SOCS1-T2A-FLT3-ITD were sacrificed when moribund, whereas mice transplanted with bone marrow expressing control GFP or SOCS1 were sacrificed at the end of the experiment at day 120. Bone marrow and spleen cells were analyzed for GFP positivity to monitor infiltration of transplants and for surface expression of lineage specific markers CD19 (immature B cells), B220 (B-cell marker), Gr1 (granulocytes), and CD117 (KIT receptor). Bone marrow cells also were stained for MPO (granulocytic marker). Values are presented as median (range).
Weak CD19 coexpression.